Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Operations (Unaudited)

v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]        
Product Revenue
Product Cost of Sales
Gross Profit
General and Administrative Expenses 1,002,949 894,297 2,069,599 1,735,982
Research and Development Expenses 236,133 873,472 746,667 2,418,985
Stock Based Compensation Expenses 2,373,655 104,854 2,432,261 189,490
Franchise Tax Expense 219,403
Impairment of Technology License 3,177,999 3,177,999
Loss from Operations (6,790,736) (1,872,623) (8,645,929) (4,344,457)
Other (Income) Expenses        
Interest and Dividend Income (100,625) (57,575) (171,965) (120,087)
Gain on Sale of Investments (19,459) (31,241) (2,176)
Change in fair value of Marketable Securities 26,584 147 7,290 1,744
Change in fair value of Derivatives Liabilities (81,000) (19,000) (591,000) (1,303,000)
Total Other (Income)/Expense (174,500) (76,428) (786,916) (1,423,519)
Loss Before Income Tax (6,616,236) (1,796,195) (7,859,013) (2,920,938)
Income Tax Benefit/(Provision)
Net Loss (6,616,236) (1,796,195) (7,859,013) (2,920,938)
Preferred Stock Dividends & Adjustments (76,716) 976,369 208,955 1,789,865
Net Loss Attributable to Common Stockholders $ (6,539,520) $ (2,772,564) $ (8,067,968) $ (4,710,803)
Basic net loss per common share $ (0.79) $ (51.10) $ (0.99) $ (187.46)
Diluted net loss per common share $ (0.79) $ (51.10) $ (0.99) $ (187.46)
Weighted average basic common stock outstanding 8,235,978 54,261 8,150,204 25,129
Weighted average diluted common stock outstanding 8,235,978 54,261 8,150,204 25,129